Myogenic Potential of Murine Embryonic Stem Cells in the Dmdmdx Mouse Model for Duchenne Muscular Dystrophy by Ayub-Guerrieri, Danielle et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Myogenic Potential of Murine Embryonic Stem 
Cells in the Dmdmdx Mouse Model for Duchenne 
Muscular Dystrophy 
Danielle Ayub-Guerrieri1, Poliana C. M. Martins-Machado1, 
Paula C.G. Onofre-Oliveira1, Lygia V. Pereira2, Camila F. Almeida1, 
Vanessa F. Lopes1 and Mariz Vainzof1 
1Laboratory of Muscle Proteins and Comparative Histopathology, Human Genome 
Research Center, Biosciences Institute, University of São Paulo 
2Dept of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo 
Brazil 
1. Introduction 
The neuromuscular disorders are a heterogeneous group of genetic diseases, causing a 
progressive loss of the motor ability. More than 30 genetically defined forms are recognized, 
and in the last decade, mutations in several genes have been reported, resulting in the 
deficiency or loss of function of different important muscle proteins. Biochemical and 
imunohistological analysis have localized these proteins in several compartments of the 
muscle fiber. The proteins dystrophin, sarcoglycans and dysferlin are sarcolemmal or peri-
sarcolemmal proteins, α2-laminin and collagen VI are extracellular matrix proteins, 
telethonin and actin are sarcomeric proteins, calpain 3 and FKRP are cytosolic enzymes, and 
emerin and lamin A/C are nuclear proteins (Vainzof et al., 2008).  
Defects in components of the dystrophin-glycoprotein complex (DGC) are known to be an 
important cause of different forms of muscular dystrophies (Ervasti & Campbell, 1993; 
Yoshida & Ozawa, 1990). The DGC is an oligomeric complex which connects the 
subsarcolemmal cytoskeleton to the extracellular matrix. The DGC consists of dystroglycan 
(α- and β-DG), sarcoglycan (α, β-, γ-, δ- and ε-SG) and syntrophin/dystrobrevin 
subcomplexes. The intracellular link of the DGC is the protein dystrophin, that plays an 
important structural role in muscle fibers. Mutations in the dystrophin gene cause the most 
common form of X-linked Duchenne muscular dystrophy (DMD) (Hoffman et al., 1987). 
Dystrophin binds its amino-terminal and rod domain to actin and with its carboxy terminal 
to the integral membrane protein β-DG. The sarcoglycan sub-complex is also linked to β-DG 
and includes α-SG, β-SG, γ-SG, and δ-SG, which are tightly associated and inserted into the 
membrane. Mutations in the genes coding the 4 SG proteins cause severe forms of limb-
girdle muscular dystrophies type LGMD2D, 2E, 2C and 2F, respectively. The peripheral 
membrane glycoprotein α-DG, a receptor for the heterotrimeric basement membrane 
protein laminin-2, binds to β-DG and so completes the connection from the inside to the 
outside of the cell (Straub & Campbell, 1997). Mutations in the LAMA2 gene, encoding the 
α2 chain of laminin-2, cause α2-laminin deficiency, and a severe form of congenital 
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muscular dystrophy (CMD1A) linked to chromosome 6q (Tomé et al., 1994). In addition, 
some forms of muscular dystrophy have recently been associated with genes encoding 
putative or known glycosyltransferases. Muscle protein analysis in these patients show a 
hypoglycoslation of α-dystroglycan and a consequent reduction of numerous ligands 
components of the extracellular matrix, such as laminin 2 (Muntoni et al., 2004). Other 
milder forms of muscular dystrophy are caused by mutations in genes coding the enzyme 
calpain 3 (LGMD2A), the sarcolemmal protein dysferlin (LGMD2B), and the sarcomeric 
protein telethonin (LGMD2G) (revision in Vainzof & Zatz, 2007).  
Several animal models, manifesting phenotypes observed in neuromuscular diseases have 
been identified in nature or generated in laboratory. These models generally present 
physiological alterations observed in human patients, and can be used as important tools for 
genetic, clinic and histopathological studies (Vainzof et al., 2008) 
The Dmdmdx mouse is the most widely used animal model for Duchenne muscular 
dystrophy (DMD). Although it is a good genetic and biochemical model, presenting total 
deficiency of the protein dystrophin in the muscle, this mouse is not useful for clinical trials, 
because of its very mild phenotype. The canine golden retriever MD model represents a 
more clinically similar model of DMD due to its larger size and significant muscle weakness.  
Autosomal recessive limb-girdle MD forms models include the SJL/J mice that develop a 
spontaneous myopathy resulting from a mutation in the Dysferlin gene, being a model for 
LGMD2B. For the human sarcoglycanopahties (SG), the BIO14.6 hamster is the spontaneous 
animal model for δ-SG deficiency, while some canine models with deficiency of SG proteins 
have also been identified. More recently, using the homologous recombination technique in 
embryonic stem cell, several mouse models have been developed with null mutations in 
each one of the 4 SG genes. All sarcoglycan-null animals display a progressive muscular 
dystrophy of variable severity, and share the property of a significant secondary reduction 
in the expression of the other members of the sarcoglycan subcomplex, and other 
components of the Dystrophin-glycoprotein complex.  
Mouse models for congenital MD include the Lama2dy/J (dystrophia-muscularis) mouse, and 
the allelic mutant Lama2dy2J/J mouse, both presenting significant reduction of α2-laminin in 
the muscle and a severe phenotype. The myodystrophy mouse (Largemyd), harbors a 
mutation in the glycosyltransferase Large, which leads to altered glycosylation of α-DG, and 
also a severe phenotype. 
The study of animal models for genetic diseases, in spite of the existence of differences in 
some phenotypes can provide important clues to the understanding of the pathogenesis of 
these disorders and are also very valuable for testing strategies for therapeutic approaches. 
In all forms of muscular dystrophies, in the early phase of the disease, there is a continuous 
process of degeneration and regeneration. The ability of adult skeletal muscle to regenerate 
has been attributed to the special properties of satellite cells. In mature skeletal muscle 
satellite cells are normally in a dormant state. Upon injury, many growth factors are secreted 
at the site of the lesion that recruits satellite cells, triggering the process of regeneration. In 
the progression of the dystrophic process, however, the endogenous satellite cell pool 
becomes exhausted and degenerated muscle fibers are replaced by fibrotic and adipose 
tissues, responsible for the observed muscle weakness. 
Therefore, stem cell therapy should be an ideal treatment for all forms of muscular 
dystrophies, in which the deficiency of a specific muscle protein leads to muscle 
degeneration. Stem cell transplantation would either prevent or break the cycles of 
degeneration and regeneration in the dystrophic process, by replacing the deficient protein 
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(Meng et al., 2011). The majority of the therapeutic trial under investigation are done using 
Duchenne muscular dystrophy as a model for, because it is the most common and severe 
mendelian form of muscular dystrophy. 
2. Stem cell therapy for muscular dystrophies  
The use of normal stem cells to rescue the effects associated with mutant tissue is a 
promising avenue of research. To correct the dystrophic phenotype healthy stem cells 
transplanted to the diseased muscles must first be attracted to the injured area, answer to 
the endogenous signals that stimulate muscle differentiation and, ultimately, fuse to 
dystrophic myofibers, or form new myotubes. Incorporated healthy nuclei would thus 
contribute to restore the normal levels of functional skeletal muscle proteins such as 
dystrophin.  
According to a recent revision by Meng et al. (2011), the ideal stem cell for treating DMD 
should fulfill several criteria, and should be able to: expandable in vivo, maintaining stem 
cell properties, be immune-competent, be systemically-delivered reaching all muscles of the 
body, survive, proliferate and migrate upon arrival within the host muscle, differentiate into 
muscle fibres, reconstitute the satellite cell pool with functional stem cells, be capable of 
expressing the missing protein, lead to improvement in muscle strength. 
The most appropriated type of stem cell for these therapies is still under investigation. 
Among adult stem cells, skeletal muscle satellite cells have been considered the only source 
of stem cells for post-natal muscle regeneration (Seale & Rudnicki, 2000). Other stem cells 
within the skeletal muscle have, however been identified, including muscle-derived stem 
cells, muscle side population cells, myogenic endothelial cells, and mesoangioblasts 
(pericytes) (Meng et al, 2011). Human skeletal muscle-derived pericytes have been shown to 
form muscle fibers, after intra-arterial transplantation in the dystrophin deficiency host mice 
(Dellavalle et al., 2007). However, in contrast, muscle-derived cells (mdcs), which are very 
similar to the pericytes, did not contribute to muscle regeneration after systemic delivery in 
mdx nu/nu host (Meng et al., 2011b). These findings illustrate the opinion of several authors 
suggesting that further work is necessary to prepare pure cell populations from skeletal 
muscle that maintain their phenotype in culture and make a robust contribution to skeletal 
muscle regeneration after systemic delivery in dystrophic mouse models (Meng et al., 
2011b) 
Among the other non-muscle stem cells, previous attempts at developing stem cell therapies 
for the treatment of DMD were performed using bone marrow and blood-derived stem 
cells, mesenchimal stem cells from other origins, and pluripotent stem cells. Bone marrow-
derived stem cells (BM) are a population of circulating cells with myogenic potential, 
present in the bone marrow, as already demonstrated as early as in the 1960s. Afterward, 
some authors confirmed that BM-derived cells can undergo myogenic differentiation and 
participate in muscle repair after injury, albeit at very low levels (Ferrari et al., 1998; Gussoni 
et al., 1999). Transplantation studies with BM cells injected into Dmdmdx mouse confirmed 
that these cells may persist in the musculature for long periods of time, and that they are 
able to express exogenous dystrophin protein. However, the amount of muscle generated 
after a BM transplant was still not therapeutically relevant, consisting of about 0.5% of 
regenerating fibers containing donor cells (Ferrari et al., 2002; Gussoni et al., 2002). 
Therefore, none of these experiments provide consistent data with the idea that transplanted 
BM cells can actually correct the dystrophic phenotype.  
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Mesenchymal stem cells from other origins have been shown to regenerate muscle fibers, 
but at a very low efficiency, in mouse models. However, some therapeutic effects have been 
observed, such as by reducing inflammation in the dystrophin deficient muscle (Ichim et al., 
2010).  
Because of their pluripotency, much attention has been devoted to the potential applications 
of Embryonic Stem (ES) (Evans & Kaufman, 1981). However, to date, ES cells have not had a 
significant impact on the development of cell-based therapies to treat muscular dystrophy. 
While a few studies have been performed in Dmdmdx mice, mainly involving the 
transplantation of embryoid bodies co-cultured with dissociated skeletal muscle, no 
evidence of long-term regenerative capacity of transplanted cells has been observed 
(Bhagavati & Xu, 2005). In table 1, the published experiments to date are summarized.  
 
 
Table 1. Summary of experiments for testing the myogenesis potential of ESCs in NMD. 
Thus, stem cell therapies for muscle disorders are still in the early days. There are many 
outstanding questions such as the immunogenic capacity of stem cells, whether local or 
systemic injections are the best route of administration in the diseased tissue, whether there 
is an optimal amount of cells to be administered, or whether the regenerative growth factors 
present in the dystrophic muscle are sufficient to promote the survival and the fusion of 
these cells to the damaged muscle (Bradley et al., 2002; Mimeault et al., 2007).  
 
In order to answer at least some of the questions summarized above, we investigated the 
capacity of ES and EB cells to generate muscle in vivo, and to express the deficient protein 
dystrophin in the Dmdmdx mouse model for DMD. 
3. In vivo experiments with ES cells and potential therapies for NMD  
3.1 ES cell culture  
The embryonic stem cell line USP-1 derived from 129/Sv mice (Sukoyan et al., 2002) was 
cultivated as described (Rohwedel et al., 1994). Briefly, cells grew on irradiated mouse 
feeder layer on gelatin-coated flasks (Nunc) in DMEM (Gibco) supplemented with 10% fetal 
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bovine serum (Hyclone) and additives (Rohwedel et al., 1994). During the isolation and 
early stages of ES cell cultivation, the medium was supplemented with human recombinant 
leukemia inhibitory factor (hLIF) at 1000 units/ml (Chemicon) and was replaced every day. 
When reached the confluence (after 4 days in culture) these cells were trypsinized, and 
transferred to another culture flask (75 cm2) previously covered by a layer of mouse 
fibroblast feeders, plated at a density of 1.0 x 106 cells/cm2 for proliferation. For 
differentiation, aliquots of 20 µl cultivation medium containing 800 cells were placed on the 
lids of Petri dishes filled with PBS, based in protocols developed by Wobus et al. in 1988 
(2002), which are based in previous differentiation by embryoid body formation and 
posterior treatment with 1% DMSO (dimethyldisulfoxide). The ES cell aggregates 
(Embryoid Bodies - EB) were cultivated in hanging drops for 2 days and subsequently in 
suspension on bacteriological Petri dishes for additional 3 days in a specific skeletal muscle 
differentiation medium (proliferation medium with 1% DMSO, but no LIF). At day 5, EBs 
were plated separately onto gelatin-coated 24 well-microwell plates for morphological 
analysis. EB were dissociated before injection and ES cells were marked with red dye 
Vybrant® Dil cell-labeling solution (Invitrogen) to facilitate their tracking in injected 
muscles. This dye efficiently label live cells, and is diluted and disappears with cells 
proliferation and cellular death.  
3.2 Animals, immunosuppression and transplantation 
Four to six-week-old Dmdmdx mice recipients were obtained from our animal house, in 
Human Genome Research Center at University of São Paulo. The mice received routine 
required cares for good health, and all experiments were approved by the research ethics 
committee of the Biosciences Institute, University of São Paulo.  
For the transplantation experiments, the Dmdmdx mice were divided into groups according to 
cell treatment (Table 2). In the immunosuppressed group, the animals received a daily dose 
of 1 mg/kg FK506 (Tacrolimus, Sigma-Aldrich) intraperitoneal injections, from the day 
before stem cells injection until the time of euthanasia.  
Each animal was injected with 1.0 x 106 ES or EB cells into the gastrocnemius muscle, or 
through intravenous injections in the tail vein.  
Animals were euthanized using CO2 chamber 2 days, 1 week, 2 weeks, 4 weeks and 8 weeks 
post-transplantation, and muscles were analyzed for dystrophin expression, and 
identification of the presence of the injected stem cells.  
3.3 Tissue processing and dystrophin analysis 
Gastrocnemius muscles were dissected and collected from all mice and additionally, several 
other tissues such as tail, liver and spleen were collected from the mice injected systemically. 
Samples of the contra lateral muscles were also collected and used as controls in the 
intramuscular injected mice. All tissue were immediately frozen in liquid nitrogen. For 
histological analysis, frozen sections of 7 μm were prepared on slides using a cryostat (Zeiss, 
Jena, Germany). 
Cryosections were stained with hematoxilin and eosin or used for immunohistochemistry to 
evaluate the expression of the muscle proteins. In brief, they were incubated with 1:100 
diluted rabbit antibody anti-dystrophin AB 15277 (Abcam) and mouse antibody anti-fetal 
myosin NCL-MHCd (Novocastra). Cy3-conjugated anti-rabbit and anti-mouse (1:100) were 
used as secondary antibodies (Sigma-Aldrich). Samples were analyzed under fluorescence 
microscopy using appropriate filters for the fluorophore. 
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Treatment: ES cells 
 
 Administration via Euthanasia and analysis 
Nonimmunosuppressed mice   
Mdx 19 Local 2 days 
Mdx 20 Local 2 week 
Mdx 21 Local 4 weeks 
Mdx 22 Systemic 2 weeks 
Mdx 23 Systemic 4 weeks 
Immunosuppressed mice   
Mdx 10 Local 1 week 
Mdx 11 Local 2 weeks 
Mdx 12 Local 4 weeks 
Mdx 13 Systemic 1 week 
Mdx 14 Systemic 2 weeks 
 
Treatment: EB cells 
 
Immunosuppressed mice Administration via Euthanasia and analysis 
Mdx 15 Local 4 weeks 
Mdx 16 Local 8 weeks 
Mdx 17 Systemic 4 weeks 
Mdx 18 Systemic 8 weeks 
Table 2. Intramuscular and systemic injected Dmdmdx mice. 
Total proteins were extracted from muscle and other tissues, separated by 6% SDS-PAGE 
polyacrylamide gel electrophoresis and were transferred onto nitrocellulose membrane (GE 
Healthcare) for 60 min at 0.35A at 4ºC. Membranes were then pre-stained in 0.2% Ponceau S, 
to ensure protein transfer and equal loading of the lanes with protein. Membranes were 
blocked with 5% nonfat milk in PBS, 0.1% Tween 20 (PBS-T) for 1 h and subsequently 
incubated with mouse antibody directed against dystrophin VP-D508 (Vector). After an 
overnight period of incubation with the primary antibody, membranes were washed three 
times with PBS-T for 10 min. The blots were then reacted with alkaline phosphatase-
conjugated secondary antibody (1:1000) for 1 h at room temperature. The detection of 
protein was done using colorimetric reaction for the enzyme, using nitroblue tetrazolium 
and 5-bromo-4-chloro-3-indolyl phosphate as substrate (Vainzof et al., 1993). 
Data on the injected cells (ES or EB cells), immunosupression and detection of cells both 
through red dye presence and DNA analysis, as well as screening for dystrophin expression 
in all injected animals are summarized in Table 3. 
To check the ability of these cells to differentiate into new muscle fibers, and to express muscle 
proteins, we analyzed recipient muscles by immunohistochemistry using an anti-dystrophin 
antibody. The immunohistochemistry revealed no significant labeling, with only scattered 
fibers partially labeled, in a pattern observed also in non-injected Dmdmdx mice (Fig. 1). Western 
blot analysis confirmed the lack of dystrophin expression in all tested animals. 
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Local injections 
ES EB cells 
Analysis Detection Analysis Detection 
 time red dye DNA Dystrophin  time red dye DNA Dystrophin 
 Mdx 19 2 d +++ - -      
Nonimmunosuppressed mice Mdx 20 2 w - - -      
 Mdx 21 4 w - - -      
 Mdx 10 1 w +++ - - Mdx 15 4 w - - - 
Immunosuppressed mice Mdx 11 2 w ++ + - Mdx 16 8 w - - - 
 Mdx 12 4 w + - -      
 Systemic injections 
 ES EB cells 
 Analysis Detection Analysis Detection 
  time red dye DNA Dystrophin  time red dye DNA Dystrophin 
Nonimmunosuppressed mice Mdx 22 2 w - - -      
 Mdx 23 4 w - - -      
Immunosuppressed mice Mdx 13 1 w + (tail) - - Mdx 17 4 w - - - 
 Mdx 14 2 w + (tail) - - Mdx 18 8 w - - - 
 




Fig. 1. Dystrophin analyses in the injected and control muscles. (A) Dystrophin 
immunofluorescence and (B) Western blotting analysis showing the positive pattern of 
labeling in normal muscle of C57black mice and the absence dystrophin in 
immunosuppresed mice injected with ES (Mdx12 and Mdx14) and EB cells (Mdx 16 and 
Mdx 18). Cells were injected in the muscle in Mdx 12 and Mdx 16, and intra-venous in Mdx 
14 and Mdx 18. 
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3.4 ES and EB cells identification 
Genomic DNA was obtained from cells and muscle tissue of injected mice. Fragments of 
injected and not injected muscles were placed in an extraction solution (100mM Tris HCl pH 
8.5; 5mM EDTA, 0.2% SDS; 200mM NaCl), containing 2.5 μl proteinase K (10mg/ml). These 
samples were kept overnight in dry bath at 55°C. The samples were subjected to 
centrifugation of 1000g for 10 minutes, and added 500 μl isopropanol in the supernatant. 
After the new centrifugation of 13500g for 15 minutes, the DNA was precipitated in TE 
buffer (TRIS-EDTA). The PCR primers used were from the same region of the genome of 
mice, which produce products of different sizes due to the presence of polymorphic regions, 
referring to strains of 129/Sv mice and Dmdmdx mice [http://www.informatics.jax.org/ 
searches/probe.cgi?37495] for the identification of ES cells. PCR conditions were 95°C 5 
minutes, with 40 cycles of 95°C 1 minute, 55°C 1 minute and 72°C 1 minute. DNA fragments 
were separated by electrophoresis in 10% acrylamide gels and marked with ethidium 
bromide to its visualization under UV transillumination. 
As almost 100% of the injected ES and EB cells were previously labeled with a red 
fluorescent dye, we analyzed the presence of these marked cells in histological sections of 
the injected mice. We identified their presence for longer periods (after 1 week) only in the 
muscle of the ES injected mice (Table 3 and Fig. 2). This may mean that the ES remained in 
the injected place.  
 
 
Fig. 2. Identification of dye labbeling of ES and EB cells. Screening for the red-labeled ES and 
EB cells injected in the different Dmdmdx mice. Intramuscular injections (Mdx 15 and Mdx 10) 
and systemically-injected (Mdx 17 and Mdx 13), showing that only the ES cells were 
identified. 
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In the animals Mdx 10, 11 and 12 (local injections of ES cells, after 1, 2 and 4 weeks), we 
noticed an increase of the muscles in the leg, and the hematoxilin-eosin (H&E) staining 
showed an intense degeneration and presence of several types of undifferentiated cells (Fig. 
3). A histopathological examination of frozen sections identified the proliferation of various 
types of immature cells, suggesting the formation of a tumor, consistent with the embryonic 






Fig. 3. Macroscopic and microscopic analyses of the muscle injected with ES cells. Analyses 
of the immunosuppressed Mdx 11, with local injections of ES cells, after 2 weeks post-
transplantation. A- A significant increase in the muscles of the injected leg was observed. B- 
Hematoxilin-eosin (H&E) staining showed the presence of several types of undifferentiated 
cells. C- Immunohistological reaction using anti-developmental myosin showed no positive 
evidence of the presence of new fibers.  
To check if the new generated tissue included differentiation into muscle fibers, we probed the 
same region described above with the antibodies against fetal myosin. However, there was no 
immunoreactivity for fetal myosin and no evidence of formation of new fibers (Fig. 3). 
3.4.1 ES cell quantification 
To investigate the presence and try to quantity of injected ES and EB cells in the muscle we 
used PCR analysis with specific primers to polymorphic markers of each cell strain. This 
method detected the presence of stem cells only in the muscle of Mdx 11 (Fig. 4A), who also 
showed an enlargement of the leg, with significant mass growth. 
The experiment revealed a 121 bp band corresponding to the molecular weight of Dmdmdx 
mice polymorphism, while a band of 142 bp is observed in the donor ES cells strain (line 4, 
Fig. 4A).  
To estimate the relative amount of the injected cells and verify their possible multiplication 
in vivo, we performed a standard curve with known concentrations of DNA from the two 
different mice strains (Fig. 4B). The ES cells strain was only detected starting with the 
concentration of 30%. In Mdx 11, the number of ES cells in the mice injected muscle were in 
a similar concentration of the limit of detection of 30% (Fig. 4A). No 142 bp band was 
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Fig. 4. DNA screening for the ES and EB presence. (A) PCR reaction for polymorphic 
markers of C57Black (Dmdmdx strain) and 129/Sv (ES and EB cells) strains in the muscles from 
all injected animals (all immunosupressed). The band of 121 bp is from the Dmdmdx strain, 
while the band of 142 bp is from of the 129/Sv strain of the ES cells. In Mdx 11 both bands 
can be observed, indicating the presence of the ES cells in the injected muscles. (B) The same 
PCR reaction, in a standard curve with known concentrations of DNA from the two 
different mice strains, showing the identification of the ES cells starting in the concentration 
of 30%. 
4. Efficient stem cell therapies for dystrophic muscle  
Replacement therapies using stem cells are emerging as promising avenues for treatment of 
genetic diseases because the transplantation of healthy stem cells into affected individuals 
can potentially rescue defects and injuries.  
The identification of mesenchymal stem cells (MSCs) as a sub-population of fibroblast-like 
adherent cells in the BM opened new perspectives for therapies for the different forma of 
muscular dystrophies, since these cells were able to differentiate into several other lineages, 
producing in vitro skeletal muscle, in addition to osteoblasts, chondroblasts, and adipocytes 
(Friedenstein et al., 1966; Prockop, 1997). Very recently, we showed that hMSC were not 
rejected when transferred to SJL/J mice by systemic and repeated injections (Vieira et al., 
2008), while mMSC intramuscularly injected cells were eliminated after 2 days in the Dmdmdx 
mouse (Ayub-Guerrieri et al., 2009). The injected cells in the SJL/J mouse were able to fuse 
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with the host muscle cell and to express the exogenous protein. However, in this previous 
study, the number of cells and injections were significantly higher and the SJL/J mouse 
model for LGMD2B presents a milder phenotype with no active muscle degeneration. This 
suggests that either the number of injected cells must be higher, or dystrophin deficient 
dystrophic muscle probably constitutes an adverse environment for the newly introduced 
cells. Thus, the high degree of degeneration, sclerosis and fat infiltration, as well as 
inflammation and activation of cascades of degeneration/regeneration genes of advanced 
muscular dystrophy reduce the efficacy of cell delivery, and can result in their poor survival 
in the injected muscles and limit the effectiveness of replacement therapies with stem cells. 
A very recent study (Gargioli et al., 2008) corroborates this hypothesis. Modified tendon 
fibroblasts expressing angiogenic factors and metalloproteinases were injected in Dmdmdx 
mice and were able to restore the vascular network and reduce collagen deposition, 
allowing efficient cell therapy in aged dystrophic mice (Gargioli et al., 2008). Therefore, we 
suggest that efficient stem cell therapies for degenerated dystrophic muscle must include 
additional procedures to improve the general health of the diseased tissue before stem cells 
can be delivered and integrated.  
Here we show that undifferentiated ES cells hold a better promise of success of retention 
than differentiated EB cells, since after intramuscular injections, ES cells, but not EB cells, 
were found in the muscle of animals after 1, 2 and 4 weeks post-injections. Additionally, 
systemic injection of both ES and EB cells were not directed nor retained by the dystrophic 
muscles. Two other reports on the use of ES cells in the treatment of DMD showed evidence 
for engraftment (Bhagavati & Xu, 2005; Darabi et al., 2008). In the first study, the 
transplantation of EB co-cultured with dissociated skeletal muscle into mdx mice was 
limited to qualitative detection of donor-derived cells in recipient muscle. However, in the 
second study, authors showed that paraxial mesoderm is not generated efficiently during ES 
differentiation induced by conventional protocols, which may further explain our lack of 
success in integrating ES cells into dystrophic muscles (Darabi et al., 2008). 
A second important question relates to the extent to which stem cells are immunogenic, since 
the safe and successful clinical will be indirectly dependent on the strength of rejection 
reactions (Mimeault et al., 2007; Trounson 2006). The first studies on the immunologic 
properties of ES cells and their derivatives have suggested their ability to induce immunologic 
tolerance (Drukker et al., 2002; Bonde & Zavazava, 2006). Because of this, we investigated the 
myogenic potential of ES and EB cells when injected into muscle of immunosuppressed mdx 
mice. Our results showed that the non differentiated ES cells were retained, while pre-
differentiated EB cells were all eliminated. Although this could happen because of the non-
integration of the EB cells, this could also suggest that even with immunosupression, more 
differentiated cells may cause a stronger immunological response than undifferentiated ES 
cells, as also suggested by other group (Drukker et al., 2002). These data are in accordance with 
recent publication showing that hESCs were highly immunogenic, triggered both cellular and 
humoral-mediated pathways, and as a result, were rapidly rejected in xenogeneic hosts. These 
authors observed that combinations of immunosuppressive regimens are necessary for stem 
cell survival in vivo (Swijnenburg et al., 2008).  
Several reports have already described that, when injected sub-cutaneousely into severe 
combined immunodeficient mice, undifferentiated ES cells will produce teratoma or 
teratocarcinoma, with derivatives of the three germ layers (Bradley et al., 2002; Mimeault et 
al., 2007; Reubinoff et al., 2000; Andrews et al., 2005; Wu et al., 2007). Here we observed an 
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increase of the leg of ES cells injected mice. Our histology findings suggest that the donor 
cells may have multiplied and have been embedded in the mice muscles, in a pattern similar 
to a teratoma. In one hand, the formation of tumor confirms the ability of these ES injected 
cells to multiplication in vivo. On the other hand, this new tissue had no muscle 
characteristics, since no dystrophin, nor developmental myosin positive fibers were 
identified. Ultimately, it is clear that the signaling environment of the severely dystrophic 
muscle was not able to induce the differentiation of stem cells into muscle cells.  
The use of single injections of stem cells for future therapies in children would have the 
significant benefit of being less invasive, and less traumatic from a clinical and 
immunological stand point. But, it also leads to a limitation in the number of injected cells, 
which can be insufficient to promote an appropriate restoration of the degenerated muscle. 
However, the finding of the injected ES cells in the recipient muscle, even using only one 
application of the same quantity of 106 cells, indicates that this number was sufficient for 
their retention in the injected muscle. Using polymorphic markers for the ES cell line we 
identified a concentration of at least 30% of these cells in the injected muscle. This result 
indicates that muscle enlargement observed in injected mice was caused by at least this 
amount of cells. In the other locally injected mice with leg enlargement, probably a lower 
amount of these cells were sufficient to promote the tumor, but this amount was not 
sufficient to allow its detection by our methodology. 
5. Conclusion 
Our results suggest that the dystrophic muscle is an adverse ambient for the homing and 
maintenance of injected stem cells, since when the “still pluripotent” stem cells were injected 
they formed tumors, and when the muscle pre-differentiated cells were injected they were 
cleared/migrated out of the tissue. Injected embryonic stem cells, therefore, must receive 
more or different stimulation from the dystrophic environment to differentiate or to fuse 
into muscle. Additional studies are necessary to increase the therapeutic potential of these 
cells in dystrophic murine models. 
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different types of human stem cell populations are capable of undergoing differentiation or trans-differentiation
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of a new approach to the treatment of genetic and developmental human diseases. Due to the fact that
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investigationally more practical than in the past. On the other hand, studies performed on stem cells, targeting
their conversion into functionally mature tissue, are not necessarily seeking to result in the clinical application
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conduct these studies to understand the molecular and cellular basis of cancer development. The fact that
cancer is one of the leading causes of death throughout the world, highlights the importance of these
researches in the fields of biology and medicine.
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